BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 17493775)

  • 1. Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.
    Gilch S; Nunziante M; Ertmer A; Schätzl HM
    Vet Microbiol; 2007 Aug; 123(4):377-86. PubMed ID: 17493775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
    Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
    J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation.
    Gilch S; Kehler C; Schätzl HM
    J Mol Biol; 2007 Aug; 371(2):362-73. PubMed ID: 17574575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation.
    Filesi I; Cardinale A; Mattei S; Biocca S
    J Neurochem; 2007 Jun; 101(6):1516-26. PubMed ID: 17542810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards cellular receptors for prions.
    Lee KS; Linden R; Prado MA; Brentani RR; Martins VR
    Rev Med Virol; 2003; 13(6):399-408. PubMed ID: 14625887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prion diseases: from molecular biology to intervention strategies.
    Nunziante M; Gilch S; Schätzl HM
    Chembiochem; 2003 Dec; 4(12):1268-84. PubMed ID: 14661267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc.
    Aguib Y; Gilch S; Krammer C; Ertmer A; Groschup MH; Schätzl HM
    Mol Cell Neurosci; 2008 May; 38(1):98-109. PubMed ID: 18387818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy.
    Heiseke A; Aguib Y; Riemer C; Baier M; Schätzl HM
    J Neurochem; 2009 Apr; 109(1):25-34. PubMed ID: 19183256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prion-protein-specific aptamer reduces PrPSc formation.
    Proske D; Gilch S; Wopfner F; Schätzl HM; Winnacker EL; Famulok M
    Chembiochem; 2002 Aug; 3(8):717-25. PubMed ID: 12203970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prion proteins: a biological role beyond prion diseases.
    Hu W; Rosenberg RN; Stüve O
    Acta Neurol Scand; 2007 Aug; 116(2):75-82. PubMed ID: 17661791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prion protein requires cholesterol for cell surface localization.
    Gilch S; Kehler C; Schätzl HM
    Mol Cell Neurosci; 2006 Feb; 31(2):346-53. PubMed ID: 16278084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
    Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
    J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP.
    Rambold AS; Miesbauer M; Olschewski D; Seidel R; Riemer C; Smale L; Brumm L; Levy M; Gazit E; Oesterhelt D; Baier M; Becker CF; Engelhard M; Winklhofer KF; Tatzelt J
    J Neurochem; 2008 Oct; 107(1):218-29. PubMed ID: 18691383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance.
    Touil F; Pratt S; Mutter R; Chen B
    J Pharm Biomed Anal; 2006 Mar; 40(4):822-32. PubMed ID: 16242887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin.
    Haviv Y; Avrahami D; Ovadia H; Ben-Hur T; Gabizon R; Sharon R
    Arch Neurol; 2008 Jun; 65(6):762-75. PubMed ID: 18541796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of prion transmission].
    Sakaguchi S
    Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncated PrP(c) in mammalian brain: interspecies variation and location in membrane rafts.
    Laffont-Proust I; Hässig R; Haïk S; Simon S; Grassi J; Fonta C; Faucheux BA; Moya KL
    Biol Chem; 2006 Mar; 387(3):297-300. PubMed ID: 16542151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.